#United States #Corvallis #Spirographic AI #polypharmacology #drug prediction

Spirographic AI LLC Launches Innovative Polypharmacology Platform

In an unprecedented move for the biotech industry, Spirographic AI, LLC has recently announced the launch of its cutting-edge tissue-specific polypharmacology prediction platform. This innovative technology, which has been validated through rigorous computational methods, promises to significantly enhance the accuracy of drug target identification and side effect predictions.

The platform boasts astonishing performance metrics, with the ability to analyze over 200 drugs across eight organ systems, achieving a primary target accuracy of 54%. This is markedly higher than the current industry standard, which typically hovers between 15% to 25%. Moreover, the platform's predictive capabilities extend to 195 different biological receptors, providing a comprehensive understanding of how various drugs interact with the body’s diverse systems.

Brandy Stoffel, MSN, RN, the founder of Spirographic AI, emphasizes the game-changing nature of this technology. Unlike conventional computational approaches that treat receptors in isolation, Spirographic AI’s platform integrates the unique microenvironment context of tissues. For instance, the behavior of a dopamine receptor in the gastrointestinal tract is distinctly different from its behavior in the brain. Recognizing these nuances is essential for accurately predicting potential side effects associated with drug therapies.

Validated Performance Metrics

The platform's validation included blind testing across an impressive array of pharmaceutical compounds representing multiple therapeutic classes. Highlights from the validation process include:

• - 54% primary target accuracy – a substantial leap above existing methodologies.
• - 44% overall polypharmacology coverage across both known therapeutic and off-target receptors.
• - 195 receptor targets analyzed concurrently across eight vital organ systems.
• - Over 19,000 novel target predictions, opening doors for drug repurposing and the discovery of new therapies.

Commercial Significance

The implications of this novel platform stretch far beyond academic interest. It has the potential to streamline various stages of the pharmaceutical development process, such as:

• - Early safety screening, where key toxicities related to cardiac, central nervous system, and organ-specific functions can be predicted even before the synthesis of compounds.
• - Drug repurposing opportunities by identifying novel targets from existing drug libraries, thus accelerating the process of bringing safe and effective medications to market.
• - Providing regulatory support with comprehensive mechanism-of-action data, essential for submission to health authorities.
• - Ensuring improved lead optimization through mapping of full target profiles early in the development phase.

As an early-stage biotechnology company, Spirographic AI is positioned at the forefront of pharmaceutical innovation with its patent-pending polypharmacology platform. The company is now exploring partnerships and licensing opportunities for this groundbreaking tool, providing a unique offering for pharmaceutical development and custom screening engagements.

About Spirographic AI

Founded with the mission to enhance drug discovery processes, Spirographic AI, LLC is dedicated to developing advanced computational tools that address the challenges of pharmaceutical safety predictions and efficacy evaluations. With the launch of their tissue-specific polypharmacology platform, they are set on transforming the landscape of drug development and safety assessments.

For additional information or partnership inquiries, visit spirographicai.com.